Literature DB >> 22511516

Derivation of a brief measure of agitation and aggression in Alzheimer's disease.

Ellen B Dennehy1, Kristin Kahle-Wrobleski, Khaled Sarsour, Denái R Milton.   

Abstract

OBJECTIVE: Neuropsychiatric symptoms, including agitation and aggression (A/A), are highly prevalent in Alzheimer's disease (AD) and are associated with increased disability, functional impairment, caregiver distress, and institutionalization. Previous psychometric work suggests that individual items of agitation, irritability, disinhibition, and aberrant motor behavior from the Neuropsychiatric Inventory (NPI) may be a valid measure of A/A in AD. We provide additional confirmation of this subscale, as well as preliminary validation of it as a measure of A/A (the NPI-4-A/A).
METHODS: The sample included 641 individuals identified from the South Carolina Alzheimer's Disease Registry and assessed to be at a nursing home level of care. Demographic and medical data were extracted from the Registry, and phone interviews were conducted with caregivers to collect additional information not included in the Registry. The primary statistical analysis was confirmatory factor analysis of the NPI-12 factor structure.
RESULTS: The standardized root mean residual and root mean square error of approximation (90% CI) values of 0.060 and 0.043 (0.030, 0.057), respectively suggest adequate model fit of the data, whereas the Tucker-Lewis index estimate of 0.779 is below the criteria for adequate model fit. All but two normalized residuals (NR) suggested adequate model fit of the data (|NR| < 2.58). NPI-4-A/A scores were higher in patients residing in nursing homes and were correlated with caregiver burden.
CONCLUSIONS: The NPI-4-A/A is proposed as a measure of A/A in AD. The utility and validity of this measure should be explored further. Improved measurement and focus on subgroups of neuropsychiatric symptoms should be integrated into interventions for AD.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 22511516     DOI: 10.1002/gps.3807

Source DB:  PubMed          Journal:  Int J Geriatr Psychiatry        ISSN: 0885-6230            Impact factor:   3.485


  5 in total

1.  Frontolimbic atrophy is associated with agitation and aggression in mild cognitive impairment and Alzheimer's disease.

Authors:  Paula T Trzepacz; Peng Yu; Phani K Bhamidipati; Brian Willis; Tammy Forrester; Linda Tabas; Adam J Schwarz; Andrew J Saykin
Journal:  Alzheimers Dement       Date:  2012-12-17       Impact factor: 21.566

2.  Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer's disease.

Authors:  Paula T Trzepacz; Jeffrey Cummings; Thomas Konechnik; Tammy D Forrester; Curtis Chang; Ellen B Dennehy; Brian A Willis; Catherine Shuler; Linda B Tabas; Constantine Lyketsos
Journal:  Int Psychogeriatr       Date:  2012-12-21       Impact factor: 3.878

3.  Medication development for agitation and aggression in Alzheimer disease: review and discussion of recent randomized clinical trial design.

Authors:  Maria Soto; Sandrine Andrieu; Fati Nourhashemi; Pierre Jean Ousset; Clive Ballard; Philippe Robert; Bruno Vellas; Constantine G Lyketsos; Paul B Rosenberg
Journal:  Int Psychogeriatr       Date:  2014-09-16       Impact factor: 3.878

4.  The influence of caregivers and behavioral and psychological symptoms on nursing home placement of persons with Alzheimer's disease: A matched case-control study.

Authors:  Candace N Porter; Margaret C Miller; Marcia Lane; Carol Cornman; Khaled Sarsour; Kristin Kahle-Wrobleski
Journal:  SAGE Open Med       Date:  2016-08-23

Review 5.  Neuropsychiatric Inventory domains cluster into neuropsychiatric syndromes in Alzheimer's disease: A systematic review and meta-analysis.

Authors:  Shaun Kuan Wei Hiu; Theophile Bigirumurame; Patience Kunonga; Andrew Bryant; Manjunadh Pillai
Journal:  Brain Behav       Date:  2022-08-08       Impact factor: 3.405

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.